0001209191-18-057255.txt : 20181105
0001209191-18-057255.hdr.sgml : 20181105
20181105172907
ACCESSION NUMBER: 0001209191-18-057255
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181102
FILED AS OF DATE: 20181105
DATE AS OF CHANGE: 20181105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hamel Lawrence G
CENTRAL INDEX KEY: 0001511368
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35068
FILM NUMBER: 181160891
MAIL ADDRESS:
STREET 1: C/O ACELRX PHARMACEUTICALS INC.
STREET 2: 575 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001427925
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-216-3500
MAIL ADDRESS:
STREET 1: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-02
0
0001427925
ACELRX PHARMACEUTICALS INC
ACRX
0001511368
Hamel Lawrence G
C/O ACELRX PHARMACEUTICALS, INC.
351 GALVESTON DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
Chief Development Officer
Common Stock
2018-11-02
4
A
0
5000
2.225
A
34795
I
By the Hamel Revocable Living Trust
Common Stock
2018-11-02
4
D
0
5000
5.00
D
29795
I
By the Hamel Revocable Living Trust
Common Stock
24371
D
Stock Option (Right to Buy)
2.225
2018-11-02
4
A
0
26125
0.00
A
2018-11-02
2028-11-02
Common Stock
26125
26125
D
Stock Option (Right to Buy)
2.225
2018-11-02
4
D
0
5000
0.00
D
2018-11-02
2028-11-02
Common Stock
5000
21125
D
Shares sold pursuant to a 10b5-1 plan.
On April 7, 2018, the reporting person was granted an option to purchase 52,250 shares of common stock. The option vests in two equal annual installments based on Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019; and the remaining 50% of the award shall vest on the one-year anniversary of the date of such FDA approval, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 26,125 shares.
/s/ Martha Adler, Attorney-In-Fact
2018-11-05